Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

S*Bio Licenses Early-Stage Cancer Drug to Tragara

publication date: Jan 21, 2009

S*BIO Pte Ltd of Singapore announced its second drug development deal this month. The company will sell a worldwide license to its early-stage cancer drug, a multi-kinase inhibitor, to Tragara Pharmaceuticals of San Diego in a transaction valued at up to $112.5 million. Two weeks ago, S*BIO optioned its JAK2 inhibitor program, including two drug candidates, to Onyx Pharmaceuticals for up to $550 million. More details...

Stock Symbols: (NSDQ: ONXX) (NYSE: NVS)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here